CORCEPT THERAPEUTICS INC Share-based Payment Arrangement, Expensed and Capitalized, Amount
CORCEPT THERAPEUTICS INC (CORT) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $29.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $29.90M, a 56.28% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $23.20M, a 5.60% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $20.86M, a 23.45% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $23.02M, a 42.13% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $84.99M, a 37.79% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $61.68M, a 25.50% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $49.15M, a 15.04% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $42.72M, a 1.03% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.90M 10-Q · filed 2026-07-29 | $53.10M 10-Q · filed 2026-07-29 | $73.96M derived: sum of 3 quarters · filed 2026-07-29 | $96.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $23.20M 10-Q · filed 2026-04-30 | $44.07M derived: sum of 2 quarters · filed 2026-04-30 | $67.09M derived: sum of 3 quarters · filed 2026-04-30 | $86.22M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $20.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.88M derived: sum of 2 quarters · filed 2026-02-24 | $63.01M derived: sum of 3 quarters · filed 2026-07-29 | $84.99M 10-K · filed 2026-02-24 |
| 2025-09-30 | $23.02M 10-Q · filed 2025-11-04 | $42.15M derived: sum of 2 quarters · filed 2026-07-29 | $64.12M 10-Q · filed 2025-11-04 | $81.02M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $19.13M 10-Q · filed 2026-07-29 | $41.10M 10-Q · filed 2026-07-29 | $58.00M derived: sum of 3 quarters · filed 2026-07-29 | $74.20M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $21.97M 10-Q · filed 2026-04-30 | $38.87M derived: sum of 2 quarters · filed 2026-04-30 | $55.07M derived: sum of 3 quarters · filed 2026-04-30 | $70.36M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $16.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $33.10M derived: sum of 2 quarters · filed 2026-02-24 | $48.39M derived: sum of 3 quarters · filed 2026-02-24 | $61.68M 10-K · filed 2026-02-24 |
| 2024-09-30 | $16.20M 10-Q · filed 2025-11-04 | $31.49M derived: sum of 2 quarters · filed 2025-11-04 | $44.78M 10-Q · filed 2025-11-04 | $57.88M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $15.29M 10-Q · filed 2025-07-31 | $28.58M 10-Q · filed 2025-07-31 | $41.69M derived: sum of 3 quarters · filed 2026-02-24 | $54.61M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $13.29M 10-Q · filed 2025-05-05 | $26.40M derived: sum of 2 quarters · filed 2026-02-24 | $39.32M derived: sum of 3 quarters · filed 2026-02-24 | $51.21M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $26.02M derived: sum of 2 quarters · filed 2026-02-24 | $37.91M derived: sum of 3 quarters · filed 2026-02-24 | $49.15M 10-K · filed 2026-02-24 |
| 2023-09-30 | $12.92M 10-Q · filed 2024-10-30 | $24.81M derived: sum of 2 quarters · filed 2024-10-30 | $36.05M 10-Q · filed 2024-10-30 | $46.65M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $11.89M 10-Q · filed 2024-07-29 | $23.13M 10-Q · filed 2024-07-29 | $33.73M derived: sum of 3 quarters · filed 2025-02-26 | $44.36M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $11.23M 10-Q · filed 2024-05-01 | $21.84M derived: sum of 2 quarters · filed 2025-02-26 | $32.47M derived: sum of 3 quarters · filed 2025-02-26 | $43.13M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $21.23M derived: sum of 2 quarters · filed 2025-02-26 | $31.90M derived: sum of 3 quarters · filed 2025-02-26 | $42.72M 10-K · filed 2025-02-26 |
| 2022-09-30 | $10.63M 10-Q · filed 2023-11-01 | $21.29M derived: sum of 2 quarters · filed 2023-11-01 | $32.12M 10-Q · filed 2023-11-01 | $43.01M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $10.66M 10-Q · filed 2023-08-02 | $21.49M 10-Q · filed 2023-08-02 | $32.38M derived: sum of 3 quarters · filed 2024-02-15 | $43.38M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $10.82M 10-Q · filed 2023-05-03 | $21.72M derived: sum of 2 quarters · filed 2024-02-15 | $32.72M derived: sum of 3 quarters · filed 2024-02-15 | $43.85M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $21.89M derived: sum of 2 quarters · filed 2024-02-15 | $33.03M derived: sum of 3 quarters · filed 2024-02-15 | $43.17M 10-K · filed 2024-02-15 |
| 2021-09-30 | $11.00M 10-Q · filed 2022-11-03 | $22.13M derived: sum of 2 quarters · filed 2022-11-03 | $32.27M 10-Q · filed 2022-11-03 | $40.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $11.13M 10-Q · filed 2022-08-04 | $21.27M 10-Q · filed 2022-08-04 | $29.76M derived: sum of 3 quarters · filed 2023-02-28 | $38.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $10.14M 10-Q · filed 2022-05-05 | $18.63M derived: sum of 2 quarters · filed 2023-02-28 | $27.38M derived: sum of 3 quarters · filed 2023-02-28 | $35.93M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $17.24M derived: sum of 2 quarters · filed 2023-02-28 | $25.79M derived: sum of 3 quarters · filed 2023-02-28 | $33.78M 10-K · filed 2023-02-28 |
| 2020-09-30 | $8.76M 10-Q · filed 2021-11-03 | $17.30M derived: sum of 2 quarters · filed 2021-11-03 | $25.29M 10-Q · filed 2021-11-03 | $32.92M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $8.55M 10-Q · filed 2021-07-29 | $16.54M 10-Q · filed 2021-07-29 | $24.16M derived: sum of 3 quarters · filed 2022-02-15 | $31.45M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $7.99M 10-Q · filed 2021-05-06 | $15.61M derived: sum of 2 quarters · filed 2022-02-15 | $22.91M derived: sum of 3 quarters · filed 2022-02-15 | $30.70M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $14.92M derived: sum of 2 quarters · filed 2022-02-15 | $22.71M derived: sum of 3 quarters · filed 2022-02-15 | $29.43M 10-K · filed 2022-02-15 |
| 2019-09-30 | $7.29M 10-Q · filed 2020-11-03 | $15.08M derived: sum of 2 quarters · filed 2020-11-03 | $21.81M 10-Q · filed 2020-11-03 | $28.16M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $7.79M 10-Q · filed 2020-08-04 | $14.52M 10-Q · filed 2020-08-04 | $20.87M derived: sum of 3 quarters · filed 2021-02-23 | $27.38M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $6.72M 10-Q · filed 2020-05-04 | $13.08M derived: sum of 2 quarters · filed 2021-02-23 | $19.59M derived: sum of 3 quarters · filed 2021-02-23 | $25.60M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $12.86M derived: sum of 2 quarters · filed 2021-02-23 | $18.88M derived: sum of 3 quarters · filed 2021-02-23 | $23.83M 10-K · filed 2021-02-23 |
| 2018-09-30 | $6.51M 10-Q · filed 2019-11-07 | $12.53M derived: sum of 2 quarters · filed 2019-11-07 | $17.48M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $6.02M 10-Q · filed 2019-08-01 | $10.97M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $4.95M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $13.36M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | $7.06M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |